NEW YORK, NY / ACCESSWIRE / January 26, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:
To: All Persons or Entities who purchased GenVec, Inc. (NASDAQ: GNVC) stock prior to January 24, 2017.
You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of GenVec, Inc. to Intrexon Corporation (NYSE: XON). Under the terms of the transaction, GenVec shareholders will receive 0.297 of a share of Intrexon Common Stock for each share of GenVec stock they own. GenVec stockholders will also receive a contingent right equal to 50% of any milestone or royalty payments received within 36 months after the closing of the transaction under GenVec's Research Collaboration and License Agreement with Novartis. To learn more about the action and your rights, go to: http://zlk.9nl.com/genvec or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
ReleaseID: 453614
